Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 797 of 5804
-
New 3-Week radiation combo could tame pancreatic cancer
Disease control OngoingThis study will observe side effects for patients who receive a 3-week course of radiation and chemotherapy for pancreas cancer. Blood samples will be collected before and after treatment to assess pancreas cancer DNA levels and its impact on outcomes.
Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New drug combo shows promise in Hard-to-Treat sarcomas
Disease control CompletedThe investigators have recently demonstrated that argininosuccinate synthase 1 (ASS1) expression is silenced in 88% of all sarcomas (n=708), and that this loss is associated with a decreased overall survival. Using the extracellular arginine depleting enzyme PEGylated arginine de…
Phase: PHASE2 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
New combo therapy hopes to tackle tough lymphoma
Disease control OngoingThis is an open-label, single arm, multicenter, dose finding, Phase Ib study in order to assess the maximum tolerated dose (MTD) and/or recommended Phase II dose (RP2D) for this combination treatment and to evaluate the general safety, tolerability, pharmacokinetic (PK), pharmaco…
Phase: PHASE1, PHASE2 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
Rural China's hypertension battle: can village doctors turn the tide?
Disease control OngoingChina Rural Hypertension Control (CRHC) Project is a cluster randomized trial that will test the effectiveness of a village doctor-led multifaceted intensive blood pressure intervention on hypertension control in 18 months (Phase 1), cardiovascular disease risk in 36 months (Phas…
Phase: NA • Sponsor: First Hospital of China Medical University • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
Could a common osteoporosis drug stop bone tumors from coming back?
Disease control Recruiting nowThe purpose of the clinical study is to investigate whether the local delivery of bisphosphonate as a surgical adjuvant can decrease the chance of a giant cell tumor of bone coming back to the same location. The hypothesis is that the local administration of bisphosphonate will d…
Phase: PHASE3 • Sponsor: St. Louis University • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Double immunotherapy plus liver blockade targets eye cancer that spreads
Disease control CompletedThis phase II trial studies ipilimumab and nivolumab with immunoembolization in treating patients with uveal melanoma that has spread to the liver. Immunotherapy with monoclonal antibodies, such as ipilimumab and nivolumab, may help the body's immune system attack the cancer, and…
Phase: PHASE2 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC
-
MS treatment showdown: does starting strong early prevent disability?
Disease control OngoingFDA-approved multiple sclerosis (MS) disease-modifying therapies (DMTs) target the relapsing phase of MS but have minimal impact once the progressive phase has begun. It is unclear if, in the relapsing phase, there is an advantage of early aggressive therapy with respect to preve…
Phase: NA • Sponsor: Johns Hopkins University • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
New hope for brain lining cancer: immunotherapy injected directly into spinal fluid
Disease control OngoingThis phase I/Ib trial studies the side effects and best dose of intrathecal nivolumab, and how well it works in combination with intravenous nivolumab in treating patients with leptomeningeal disease. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body'…
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
Can lung cancer patients safely stop immunotherapy after 6 months?
Disease control CompletedNon Small Cell lung cancer (NSCLC) remains the first cause of death by cancer in the World. For the patients presenting a NSCLC stage IV, the median of survival is about 15 months today. The chemotherapy with platinum is the standard treatment for these patients but immunotherapy…
Phase: PHASE3 • Sponsor: Intergroupe Francophone de Cancerologie Thoracique • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
New cocktail of immune drugs shows promise for tough prostate cancer
Disease control CompletedBackground: Immunotherapy drugs help the body to fight cancer. Scientists think that combining some of these drugs will make them work better than when used alone. This may be true for many types of cancer, including castration-resistant prostate cancer (CRPC). Objective: To t…
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
New combo therapy aims to stop sarcoma return in kids and young adults
Disease control Recruiting nowThis research is being done to find out if an investigational drug, Nivolumab, can be safely administered after a "half-matched" (haplo) bone marrow transplant (BMT), and if the investigational drug will help to prevent or delay relapse or progression of sarcomas. In this study i…
Phase: PHASE1, PHASE2 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
Blasting pancreatic tumors with extra radiation may open door to surgery
Disease control OngoingThis study is being done to test whether receiving a dose of radiation that is higher than the standard dose, in combination with chemotherapy, improves the chance of becoming a candidate for surgery and improves the chance of extending the patient's life.
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Could an immunotherapy drug tame liver cancer in hepatitis b patients?
Disease control OngoingThis is a single-arm Phase II trial of pembrolizumab in patients with hepatitis B virus-related hepatocellular carcinoma with parallel study on baseline and serial change in the immune environment. Subjects should have a confirmed diagnosis of HCC (in accordance with the AASLD g…
Phase: PHASE2 • Sponsor: CCTU • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
HIV heart risk targeted: new drug shows promise in reducing arterial inflammation
Disease control CompletedAtherosclerosis in the setting of HIV infection is distinct and includes increased vascular inflammation, worsened endothelial function, and a predominance of non-calcified plaque. These outcomes can be assessed using specialized noninvasive imaging which strongly predict future …
Phase: PHASE3 • Sponsor: University of California, San Francisco • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
Could your own tumor cells fight cancer? new trial tests immune cell therapy
Disease control OngoingThis phase II trial studies how well autologous tumor infiltrating lymphocytes LN-145 (LN-145) or LN-145-S1 works in treating patients with ovarian cancer, triple negative breast cancer (TNBC), anaplastic thyroid cancer, osteosarcoma, or other bone and soft tissue sarcomas that d…
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
New three-step combo targets tough head and neck cancers
Disease control OngoingThe purpose of this study is to evaluate the results of treating patients with HPV-unrelated head and neck squamous cell carcinoma with neoadjuvant single-agent palbociclib, followed by chemoradiation (either cisplatin + IMRT or cetuximab + IMRT depending on patient characteristi…
Phase: PHASE2 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Double-Drug attack shows promise for tough prostate cancer
Disease control OngoingThis randomized phase II trial studies how well abiraterone acetate and antiandrogen therapy, with or without cabazitaxel and prednisone, work in treating patients with castration-resistant prostate cancer previously treated with docetaxel that has spread to other parts of the bo…
Phase: PHASE2 • Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug combo shows promise for tough liver cancer
Disease control CompletedThis is a non-randomized, open-label, multi-site phase II therapeutic trial of pembrolizumab and bavituximab in patients with locally advanced HCC. Locally advanced or metastatic HCC is defined as disease that is not amenable to surgical and/or locoregional therapies. Subjects mu…
Phase: PHASE2 • Sponsor: David Hsieh • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
New drug combo shows promise for Hard-to-Treat CLL
Disease control OngoingThis is an open-label, multicenter, Phase II study to investigate the efficacy and safety of venetoclax in combination with Rituximab/hyaluronidase human in participants with relapsed or refractory chronic lymphocytic leukemia (CLL).
Phase: PHASE2 • Sponsor: Georgetown University • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
Cancer drug nivolumab takes on EBV-Linked tumors in new trial
Disease control Recruiting nowBackground: The drug Nivolumab has been approved to treat some cancers. Researchers want to see if it can slow the growth of other cancers. They want to study its effects on cancers that may have not responded to chemotherapy or other treatments. Objectives: To see if Nivoluma…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC